화학공학소재연구정보센터
홈 로그인 로그아웃 연락처 사이트맵
Macromolecular Research, Vol.16, No.1, 15-20, January, 2008
Export Citation
Tumoral Accumulation of Long-Circulating, Self-Assembled Nanoparticles and Its Visualization by Gamma Scintigraphy
Yong Woo Cho, Yoo-Shin Kim1, In-San Kim1, Rang-Woon Park1, †, Seung Jun Oh2, Dae Hyuk Moon2, Sang Yoon Kim2, and Ick Chan Kwon3
  • Department of Chemical Engineering, Hanyang University, Ansan 426-791, Korea
  • 1Advanced Medical Technology Cluster for Diagnosis and Prediction, Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu 700-422, Korea
  • 2Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Korea
  • 3Biomedical Research Center, Korea Institute of Science and Technology, Seoul 136-791, Korea
E-mail:
The enhanced permeability and retention (EPR) effect is used extensively for the passive targeting of many macromolecular drugs for tumors. Indeed, the EPR concept has been a gold standard in polymeric anticancer drug delivery systems. This study investigated the tumoral distribution of self-assembled nanoparticles based on the EPR effect using fluorescein and radio-labeled nanoparticles. Self-assembled nanoparticles were prepared from amphiphilic chitosan derivatives, and their tissue distribution was examined in tumor-bearing mice. The size of the nanoparticles was controlled to be 330 nm, which is a size suited for opening between thedefective endothelial cells in tumors. The long-circulating polymer nanoparticles were allowed to gradually accumulate in the tumors for 11days. The amount of nanoparticles accumulated in the tumors was remarkably augmented from 3.4%ID/g tissue at 1 day to 25.9%ID/g tissue at 11 days after i.v. administration. The self-assembled nanoparticles were sustained at a high level throughout the 14 day experimental period, indicating their long systemic retention in the blood circulation. The γ-images provided clear evidence of selective tumor localization of the 131I-labeled nanoparticles. Confocal microscopy revealed the fluorescein-labeled nanoparticles to be preferentially localized in the perivascular regions, suggesting their extravasation to the tumors through the hyperpermeable angiogenic tumor vasculature. This highly selective tumoral accumulation of nanoparticles was attributed to the leakiness of the blood vessels in the tumors and their long residence time in the blood circulation.
Keywords:nanoparticles;EPR effect;tumor targeting;long-circulating;gamma scintigraphy
  1. Matsumura Y, Maeda H, Cancer Res., 46, 6387 (1986)
  2. Maeda H, Adv. Drug Deliv. Rev., 6, 181 (1991)
  3. Maeda H, Seymour LW, Miyamoto Y, Bioconjugate Chem., 3, 351 (1992)
  4. Satchi-Fainaro R, Puder M, Davies JW, Tran HT, Sampson DA, Greene AK, Corfas G, Folkman J, Nat. Med., 10, 255 (2004)
  5. Julyan PJ, Seymour LW, Ferry DR, Daryani S, Boivin CM, Doran J, David M, Anderson D, Christodoulou C, Young AM, Hesselwood S, Kerr DJ, J. Control. Release, 57, 281 (1999)
  6. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J, Clin. Orthop. Rel. Res
  7. Li C, Yu DF, Newman RA, Cabral F, Stephens LC, Hunter N, Milas L, Wallace S, Cancer Res., 58, 2404 (1998)
  8. Maeda H, Fang J, Inutsuka T, Kitamoto Y, Int. Immunopharmacol., 3, 319 (2003)
  9. Kim K, Kim JH, Kim S, Chung H, Choi K, Kwon IC, Macromol. Res., 13(3), 167 (2005)
  10. Barratt GM, Pharm. Sci. Technol. Today, 3, 163 (2000)
  11. Moghimi SM, Hunter AC, Murray JC, Pharmacol. Rev., 53, 283 (2001)
  12. Duncan R, Nat. Rev. Drug Discov., 2, 347 (2003)
  13. Brannon-Peppas L, Blanchette JO, Nat. Rev. Drug Discov., 56, 1649 (2004)
  14. Park JH, Kwon S, Lee M, Chung H, Kim JH, Kim YS, Park RW, Kim IS, Seo SB, Kwon IC, Jeong SY, Biomaterials, 27, 119 (2006)
  15. Kaul G, Amiji M, J. Drug Target., 12, 585 (2004)
  16. Son YJ, Jang JS, Cho YW, Chung H, Park RW, Kwon IC, Kim IS, Park JY, Seo SB, Park CR, Jeong SY, J. Control. Release, 91, 135 (2003)
  17. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK, Cancer Res., 55, 3752 (1995)
  18. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK, Proc. Natl. Acad. Sci. USA, 95, 4607 (1998)
  19. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM, Am. J. Pathol., 156, 1363 (2000)
  20. Monskey WL, Fukumura D, Gohongi T, Ancukiewcz M, Weich HA, Torchillin VP, Yuan F, Jain RK, Cancer Res., 59, 4129 (1999)
  21. McDonald DM, Baluk P, Cancer Res., 62, 5381 (2002)
  22. Lee M, Cho YW, Park JH, Chung H, Jeong SY, Choi K, Moon DH, Kim SY, Kim IS, Kwon IC, Colloid Polym. Sci., 284, 506 (2006)
  23. Cho YW, Park SA, Han TH, Son DH, Park JS, Oh SJ, Moon DH, Cho KJ, Ahn CH, Byun Y, Kim IS, Kwon IC, Kim SY, Biomaterials, 28, 1236 (2007)
  24. Manotham K, Tanaka T, Matsumoto M, Ohse T, Miyata T, Inagi R, Kurokawa K, Fujita T, Nangaku M, J. AM. Soc. Nephrol., 15, 1277 (2004)
  25. Ching LM, Zwain S, Baguley BC, Br. J. Cancer, 90, 906 (2004)
  26. Williams KJ, Tefler BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, Wedge SR, Clin. Cancer Res., 10, 8587 (2004)
  27. Braet F, Dezanger R, Baekeland M, Crabbe E, van der Smissen P, Wisse E, Hepatology, 21, 180 (1995)
  28. Juliano RL, Adv. Drug Deliv. Rev., 2, 31 (1988)
  29. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK, Cancer Res., 54, 3352 (1994)
  30. Yokoyama M, Okano T, Sakurai Y, Ekimoto H, Shibazaki C, Kataoka K, Cancer Res., 51, 3229 (1991)
  31. Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, Kataoka K, Cancer Res., 63, 8977 (2003)